Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,586.70 | 15.30 | 0.18% |
| CAC 40 | 7,830.33 | 34.11 | -0.43% |
| DAX 40 | 24,040.67 | 41.50 | 0.17% |
| Dow JONES (US) | 41,859.09 | 1.35 | -0.00% |
| FTSE 100 | 8,747.90 | 8.64 | 0.10% |
| HKSE | 23,601.26 | 56.95 | 0.24% |
| NASDAQ | 18,925.73 | 53.09 | 0.28% |
| Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
| NZX 50 Index | 12,596.50 | 65.75 | -0.52% |
| S&P 500 | 5,842.01 | 2.60 | -0.04% |
| S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
| SSE Composite Index | 3,348.37 | 31.82 | -0.94% |